载脂蛋白A1通过B类清道夫受体I依赖机制调节实验性自身免疫性葡萄膜炎中Teff/Treg平衡
该研究在实验性自身免疫性葡萄膜炎(EAU)小鼠模型中观察到,给予载脂蛋白A1(APOA1)可减轻EAU,抑制致病性CD4+ T细胞扩增及效应T细胞向视网膜浸润,并抑制T细胞增殖与Th1分化、促进Treg分化。机制上APOA1的作用由B类清道夫受体I(SR-BI)及下游磷脂酰肌醇3-激酶/蛋白激酶B、p38丝裂原活化蛋白激酶和核因子-κB信号介导。作者认为APOA1可作为自身免疫性葡萄膜炎的候选治疗选择。
要点
- APOA1给药可减轻实验性自身免疫性葡萄膜炎(EAU)。
- APOA1抑制引流淋巴结和脾脏中致病性CD4+ T细胞扩增,减少效应T细胞向视网膜浸润。
- APOA1的作用部分通过SR-BI及下游PI3K/Akt、p38 MAPK和NF-κB信号介导。
核心结论
- APOA1通过部分依赖SR-BI的机制调节Teff/Treg平衡,从而减轻EAU。
- 作者认为APOA1可作为自身免疫性葡萄膜炎的候选治疗选择。
研究设计与样本
- 用光感受器间维生素A类结合蛋白1-20免疫小鼠建立EAU模型,并给予APOA1或溶媒对照。
- 分析视网膜、引流淋巴结和脾脏,并用分离的T细胞进行体外增殖、分化和功能实验。
- 使用选择性抑制剂和通路激动剂研究信号通路,并检测APOA1对葡萄膜炎患者外周血单个核细胞的作用。
主要发现
- 给予APOA1可改善EAU。
- APOA1抑制引流淋巴结和脾脏中致病性CD4+ T细胞扩增,减少效应T细胞向视网膜浸润。
- APOA1在体外抑制T细胞增殖和辅助性T细胞1分化,并促进调节性T细胞分化。
- APOA1限制脂多糖刺激的外周血单个核细胞产生炎症细胞因子。
- 机制研究显示APOA1的作用由SR-BI及下游磷脂酰肌醇3-激酶/蛋白激酶B、p38丝裂原活化蛋白激酶和核因子-κB信号介导。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Experimental autoimmune uveitis (EAU) is a representative animal model of human uveitis. In this study, we investigated whether apolipoprotein A1 (APOA1) can alleviate EAU and explored its underlying mechanism. METHODS: Mice were immunized with interphotoreceptor retinoid-binding protein 1-20 and treated with APOA1 or vehicle. The retinas, draining lymph nodes (DLNs), and spleens were analyzed. Isolated T cells were used for proliferation, differentiation, and function assays in vitro. Selective inhibitors and pathway agonists were used to study signaling pathways. The effect of APOA1 on peripheral blood mononuclear cells (PBMCs) from uveitis patients was also examined. RESULTS: Administration of APOA1 ameliorated EAU. APOA1 suppressed pathogenic CD4+ T cell expansion in DLNs and spleen, and decreased the infiltration of effector T (Teff) cells into retina. APOA1 also inhibited T cell proliferation and T helper 1 cell differentiation in vitro and promoted regulatory T (Treg) cell differentiation. APOA1 restricted inflammatory cytokine production from lipopolysaccharide-stimulated PBMCs. Mechanistic studies revealed that the effect of APOA1 was mediated by scavenger receptor class B type I (SR-BI) and downstream signals including phosphatidylinositol 3-kinase/Protein kinase B (PKB, or Akt), p38 mitogen-activated protein kinase, and nuclear factor-κB. CONCLUSIONS: APOA1 ameliorates EAU by regulating the Teff/Treg partially through SR-BI. Our results suggest that APOA1 can be a therapeutic alternative for autoimmune uveitis.
引用
- Huang H, Li Z, Huang J, et al. Apolipoprotein A1 Modulates Teff/Treg Balance Through Scavenger Receptor Class B Type I-Dependent Mechanisms in Experimental Autoimmune Uveitis. Invest Ophthalmol Vis Sci. 2022. PMID: 35881406. doi:10.1167/iovs.63.8.23
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。